| 摘要 |
75 Abstract This invention relates generally to a method of diagnosis and prognosis, in particular staging and/or typing and/or predicting outcome, for distinguishing between a benign prostate hyperplasia and a prostate cancer and between an hormone sensitive and an hormone refractory prostate cancer condition and specifically to identification of differentially methylated CpG islands in the regulatory regions surrounding the transcriptional start site of at least one marker gene of the present invention as a diagnostic and/or prognostic indicator of prostate cancer (PrCa) and for distinguishing androgen-refractory from androgen sensitive prostate cancer. The marker genes of the present invention comprise TDRD1, RARB, GSTP1, APC, CCND2 PTGS2, BCL2, RASSF1, LGALS3, CDH13, PITX2, and HOXD3. This invention relates more specifically to the detection of hypomethylation of said regulatory region of the Marker gene TDRD1 together with the hypermethylation of at least one marker gene, selected from the list: RARB, GSTP1, APC, CCND2 PTGS2, BCL2, RASSF1, LGALS3, CDH13, PITX2, and HOXD3. Additional hypomethylation markers of this invention comprise MAGEA2 and/or MAGEA11), and additional hypermethylation markers of this invention comprise TDRD5, TBX20, SOX1 and/or MSMB, with MSMB being hypermethylated in non-CpG islands. This invention further relates to the prediction, prognosis or diagnosis of prostate cancer, including metastasis, more particularly in patients with prostate cancer. Marker genes have been identified of which promoter regions containing differentially methylated regions, compared to a reference sample, which are indicative for the prediction or prognosis of prostate cancer. |
